Impact of COVID-19 on leprosy reactions and of leprosy treatments on COVID-19 severity
Indian J Dermatol Venereol Leprol
.
2023 Jan-Frebuary;89(1):133-134.
doi: 10.25259/IJDVL_1235_2021.
Authors
Mayra Ianhez
1
,
Selma Rps Cerqueira
2
,
Ciro Martins Gomes
2
,
Carolina C Talhari
3
,
Paulo R Criado
4
,
Caio Cs Castro
5
,
Paulo M Ramos
6
,
Hélio A Miot
6
Affiliations
1
Departamento de Medicina Tropical e Dermatologia, Universidade Federal de Goiás (UFG), Goiânia, Goiás, Brazil.
2
Department of Dermatology, Faculdade de Medicina de Brasília, Universidade de Brasília (UnB), Brasília, Federal District, Brazil.
3
Department of Dermatology, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
4
Department of Dermatology, Centro Universitário Faculdade de Medicina do ABC and Alergoskin Alergia e Dermatologia, Santo André, São Paulo, Brazil.
5
School of Medicine, Department of Dermatology, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil.
6
Department of Dermatology, UNESP Medical School, Botucatu, São Paulo, Brazil.
PMID:
36331835
DOI:
10.25259/IJDVL_1235_2021
No abstract available
Publication types
Letter
Comment
MeSH terms
COVID-19*
Humans
Leprostatic Agents / therapeutic use
Leprosy* / complications
Leprosy* / diagnosis
Leprosy* / drug therapy
Substances
Leprostatic Agents